Condition: B-cell Acute Lymphoblastic Leukemia · Sponsor: Cellectis S.A.
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
This description comes directly from the study's public registry record.
Cellectis Central Contact · +1 (347) 752-4044 · clinicaltrials@cellectis.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles (UCLA) - Medical Center | Los Angeles, California, United States | Recruiting |
| University of Colorado - Aurora Cancer Center | Aurora, Colorado, United States | Recruiting |
| Sarah Cannon - Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Weill Medical College of Cornell University | New York, New York, United States | Withdrawn |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Sarah Cannon - HCA Research Institute | Nashville, Tennessee, United States | Recruiting |
| Sarah Cannon - St. David's South Austin Medical Center | Austin, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04150497